Truist Financial initiated coverage on shares of Curis (NASDAQ:CRIS – Free Report) in a report published on Friday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $26.00 price objective on the biotechnology company’s stock.
CRIS has been the topic of several other reports. StockNews.com started coverage on shares of Curis in a report on Tuesday, October 3rd. They set a hold rating on the stock. Cantor Fitzgerald reissued an overweight rating and set a $60.00 price target on shares of Curis in a research report on Thursday, September 7th. Finally, HC Wainwright restated a buy rating on shares of Curis in a research note on Monday, September 25th.
Curis Trading Up 15.1 %
Institutional Investors Weigh In On Curis
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. CM Management LLC grew its holdings in Curis by 120.0% during the first quarter. CM Management LLC now owns 550,000 shares of the biotechnology company’s stock worth $328,000 after acquiring an additional 300,000 shares during the period. LPL Financial LLC increased its stake in Curis by 46.6% in the 2nd quarter. LPL Financial LLC now owns 108,554 shares of the biotechnology company’s stock worth $90,000 after purchasing an additional 34,500 shares in the last quarter. Virtu Financial LLC increased its stake in Curis by 235.8% in the 2nd quarter. Virtu Financial LLC now owns 70,848 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 49,748 shares in the last quarter. Two Sigma Investments LP increased its stake in Curis by 175.2% in the 1st quarter. Two Sigma Investments LP now owns 116,477 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 74,149 shares in the last quarter. Finally, Bank of America Corp DE increased its stake in Curis by 56.6% in the 1st quarter. Bank of America Corp DE now owns 112,227 shares of the biotechnology company’s stock worth $67,000 after purchasing an additional 40,583 shares in the last quarter. 25.41% of the stock is currently owned by institutional investors.
Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.
- Five stocks we like better than Curis
- How Investors Can Find the Best Cheap Dividend Stocks
- The most upgraded stocks in November have two things in common
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- Monday.com rocked earnings like it’s the weekend
- Airline Stocks – Top Airline Stocks to Buy Now
- Plan to own one retailer? Make it this one
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.